



The Neurotoxicity of Biomedicines

Guest Editor:

Dr. Wayne G. Carter

Clinical Toxicology Research
Group, School of Medicine,
University of Nottingham,
Nottingham, UK

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Neurotoxicity arises when excessive exposure to natural or synthetic substances detrimentally affects the functioning of the peripheral and/or central nervous system. Biomedicines or ethnomedicines may be neurotoxic by a number of molecular mechanisms, for example, via the induction of redox stress, and may trigger or contribute to neurodegeneration and neuronal death. In this Special Issue entitled 'The Neurotoxicity of Biomedicines' we are requesting manuscripts or review articles that cover agents that initiate or propagate neurotoxicity. This includes the neurotoxicity of biomedicines and ethnomedicines as pure or partially pure extracts or fractions, and the neurotoxicity of synthetic medicines. The evaluation of neurotoxicity will consider agent application to cell lines or administration to animals, or the neurotoxicity of an agent evidenced from human studies. The collation of novel research studies and review articles covering neurotoxicity will produce a useful resource of cutting-edge research in this field to help evaluate the next generation of biomedicines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)